ストックスクリーナーアプリを入手
3.04
1.33%
0.04
プレマーケット:
3.01
-0.03
-0.99%
Editas Medicine Inc (EDIT) 最新ニュース
Chardan Capital Boosts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat
Editas Medicine (NASDAQ: EDIT) cuts Q1 2026 loss as spending falls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results - MarketBeat
Editas Medicine Releases Q1 2026 Financial Results - AlphaStreet
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Editas Medicine (Nasdaq: EDIT) trims Q1 2026 net loss to $25M - Stock Titan
Editas: Q1 Earnings Snapshot - Barchart.com
Editas targets human testing this year for a one-shot cholesterol gene edit - Stock Titan
Editas Medicine Announces First Quarter 2026 Results and Business Updates - Yahoo Finance
Editas Medicine (EDIT) to Release Quarterly Earnings on Monday - MarketBeat
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) Rating Increased to Hold at Wall Street Zen - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving AverageHere's Why - MarketBeat
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDITAS Medicine (NASDAQ: EDIT) advances EDIT-401; IND target mid-2026 - Stock Titan
Editas Medicine (NASDAQ: EDIT) details 2026 virtual meeting, pay vote and in vivo strategy - Stock Titan
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Editas Medicine to present preclinical data on EDIT-401 therapy By Investing.com - Investing.com India
Editas Medicine to present preclinical data on EDIT-401 therapy - Investing.com UK
Upcoming Editas Medicine presentations focus on gene editing research advances - Traders Union
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - ChartMill
Attachment - GlobeNewswire
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow | Editas Medicine Inc - Stock Titan
Is Editas Medicine going to $0? - MSN
Editas Medicine : Corporate Effectiveness Report April 2026 (b08b29) - marketscreener.com
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Editas (EDIT) up 3.8% since last earnings report: Can it continue? - MSN
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell - MarketBeat
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026 - Minichart
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com India
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com - Investing.com South Africa
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young - Stock Titan
Growth Value: How correlated is Editas Medicine Inc to the S P500Sell Signal & Safe Capital Investment Plans - baoquankhu1.vn
Can Editas Medicine (EDIT) Stock Beat the Market | Price at $2.73, Up 2.25%Institutional Grade Picks - Cổng thông tin điện tử tỉnh Lào Cai
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Eastern Progress
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):